论文部分内容阅读
目的:初步评价临床T2期肾细胞癌患者行保留肾单位手术(NSS)治疗的安全性及疗效。方法:回顾性分析2011年6月~2014年3月施行NSS治疗的16例临床T2期肾细胞癌患者临床资料,对这些患者的一般资料、手术时间、术中缺血时间、术中出血量、术后并发症、控瘤及肾功能保护效果等情况进行评价。结果:全部手术获得成功,手术时间(216±11)min;冷缺血时间(27±2)min;术中出血量(288±30)ml。术后无严重并发症。随访6~39个月,平均(20.9±10.9)个月,所有患者均无瘤生存,血清Cr水平上升(16.6±15.5)μmol/L。结论:对临床T2期肾细胞癌患者施行NSS技术上可行,短期临床效果良好。
Objective: To evaluate the safety and efficacy of conservative nephron sparing (NSS) in clinical stage T2 renal cell carcinoma. Methods: The clinical data of 16 patients with clinical stage T2 renal cell carcinoma treated with NSS from June 2011 to March 2014 were retrospectively analyzed. The general data, operation time, intraoperative ischemic time, intraoperative blood loss , Postoperative complications, tumor control and renal function protection and other conditions were evaluated. Results: All surgeries were successful. The operative time (216 ± 11) min, cold ischemia (27 ± 2) min and intraoperative blood loss (288 ± 30) ml, respectively. No serious complications after surgery. The patients were followed up for 6 to 39 months with an average of (20.9 ± 10.9) months. All patients had no tumor-free survival and serum Cr level increased by (16.6 ± 15.5) μmol / L. Conclusion: The clinical use of NSS in patients with T2-phase renal cell carcinoma is feasible and short-term clinical results are good.